Sex Hormone-Binding Globulin and Risk of Incident Dementia in Middle-Aged to Older Women: Results from the UK Biobank Cohort Study

Huang, Junlin; Xu, Bingyan; Chen, Xiaomin; Yang, Linjie; Liu, Deying; Lin, Jiayang; Liu, Yating; Lei, Xuzhen; Huang, Chensihan; Dou, Weijuan; Guo, Dan; Wei, Xueyun; Zhang, Peizhen; Huang, Yan; Gu, Xuejiang; Zhang, Huijie

doi:10.1159/000533929

Cited by 3 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study indicates that there exists a synergistic effect between COMT and APOE in individuals who have been diagnosed with MCI and AD (Huang et al, 2024). The gender-specific effect was found, whereby the interaction between COMT and APOE was more prominent in female individuals who have been diagnosed with AD (Reynolds et al, 1999).…”

Section: Investigates the Potential Association Between Estrogen Estr...mentioning

confidence: 96%

Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough

Rishabh,

Rohilla,

Bansal

et al. 2024

Eur J of Neuroscience

View full text Add to dashboard Cite

In females, Alzheimer's disease (AD) incidences increases as compared to males due to estrogen deficiency after menopause. Estrogen therapy is the mainstay therapy for menopause and associated complications. Estrogen, a hormone with multifaceted physiological functions, has been implicated in AD pathophysiology. Estrogen plays a crucial role in amyloid precursor protein (APP) processing and overall neuronal health by regulating various factors such as brain‐derived neurotrophic factor (BDNF), intracellular calcium signalling, death domain‐associated protein (Daxx) translocation, glutamatergic excitotoxicity, Voltage‐Dependent Anion Channel, Insulin‐Like Growth Factor 1 Receptor, estrogen‐metabolising enzymes and apolipoprotein E (ApoE) protein polymorphisms. All these factors impact the physiology of postmenopausal women. Estrogen replacement therapies play an important treatment strategy to prevent AD after menopause. However, use of these therapies may lead to increased risks of breast cancer, venous thromboembolism and cardiovascular disease. Various therapeutic approaches have been used to mitigate the effects of estrogen on AD. These include hormone replacement therapy, Selective Estrogen Receptor Modulators (SERMs), Estrogen Receptor Beta (ERβ)‐Selective Agonists, Transdermal Estrogen Delivery, Localised Estrogen Delivery, Combination Therapies, Estrogen Metabolism Modulation and Alternative Estrogenic Compounds like genistein from soy, a notable phytoestrogen from plant sources. However, mechanism via which these approaches modulate AD in postmenopausal women has not been explained earlier thoroughly. Present review will enlighten all the molecular mechanisms of estrogen and estrogen replacement therapies in AD. Along‐with this, the association between estrogen, estrogen‐metabolising enzymes and ApoE protein polymorphisms will also be discussed in postmenopausal AD.

show abstract

Section: Investigates the Potential Association Between Estrogen Estr...mentioning

confidence: 96%

Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough

Rishabh,

Rohilla,

Bansal

et al. 2024

Eur J of Neuroscience

View full text Add to dashboard Cite

show abstract

Association between sex hormone binding globulin and metabolic syndrome in US adults: insights from National Health and Nutrition Examination Survey (NHANES) 2013–2016

Yang,

Wang,

Huang

et al. 2024

Diabetol Metab Syndr

View full text Add to dashboard Cite

Background Metabolic syndrome (MetS) presents a notable public health challenge on a global scale, exerting a considerable impact on individuals’ health and quality of life. There is mounting evidence indicating a robust association between MetS and levels of sex hormones. Therefore, the study aims to explore the relationship between sex hormone binding-globulin (SHBG) and MetS, and to provide evidence that could inform the development of effective prevention strategies for MetS. Methods Data for this cross-sectional investigation were collected during the 2013–2016 cycle of the National Health and Nutrition Examination Survey (NHANES), from which 5,499 adults were sampled. The criteria established by the Adult Treatment Program III of the National Cholesterol Education Program were utilized to define MetS. SHBG levels were measured using a standardized technique. Multivariate-adjusted logistic regression, multivariate restricted cubic spline, and threshold effect analyses were utilized to investigate the association between SHBG levels and MetS. Moreover, the stratified analyses and interaction tests of covariables were presented in a forest plot. Finally, sensitivity analysis was utilized to ensure the robustness of the results. Results Overall, 1822 participants had MetS. After adjusting for possible confounders, SHBG levels were associated with MetS (Odds ratio [OR], 0.984; 95% confidence interval [CI], 0.981–0.986; P < 0.01). The multivariate restricted cubic spline analysis demonstrated a non-linear association between SHBG and MetS (P < 0.001). With two piecewise regression models, the adjusted OR of developing MetS was 0.964 (95% CI, 0.959–0.969; P < 0.001) among people with SHBG < 76.653 nmol/L, but there was no correlation between SHBG and MetS in participants with SHBG ≥ 76.653 nmol/L. The stability of the association between SHBG levels and MetS was confirmed using subgroup analysis and sensitivity analyses. Conclusions Our results suggest that reduced SHBG levels are associated with an increased prevalence of MetS in adults, particularly when SHBG levels are below 76.653 nmol/L. More investigation is required to understand comprehend the mechanisms underlying these results and to delve into their clinical implications.

show abstract

Correlation of Sex Hormone Binding Globulin with Metabolic Syndrome in US Adults: Insights from National Health and Nutrition Examination Survey (NHANES) 2013–2016

Yang,

Wang,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Metabolic syndrome (MetS) poses a significant public health challenge worldwide, significantly impacting the health and quality of life of individuals. Increasing evidence suggests a strong correlation between MetS and sex hormone levels. The objective of this study is to explore the possible relationship between sex hormone binding globulin (SHBG) and Mets, aiming to furnish evidence that could inform the development of effective prevention strategies for Mets. Methods The data for this cross-sectional investigation were collected during the 2013–2016 cycle of the National Health and Nutrition Examination Survey (NHANES), from which 5,499 adults were sampled. The criteria established by the Adult Treatment Program III of the National Cholesterol Education Program were utilized to define MetS. SHBG were measured using a standardized technique. Multivariable-adjusted Logistic regression analysis, curve fitting, and threshold effects analysis were utilized to investigate the association between SHBG levels and Mets. Moreover, the stratified analyses and interaction tests of covariables were presented in the forest plot. Finally, sensitivity analysis was utilized to ensure the the robustness of the results. Results Among the participants, 1822 those had Mets. After adjusting for possible confounders, the SHBG level was associated with Mets (Odds ratio [OR], 0.984; 95% confidence interval [CI], 0.981–0.986; P < 0.01). The multivariable restricted cubic spline demonstrated a non-linear association between SHBG and Mets (P < 0.001). With two piecewise regression models, the adjusted OR of developing Mets was 0.964 (95% CI, 0.959–0.969; P < 0.001) among people with SHBG < 76.653nmol/L, but there was no correlation between SHBG and Mets in participants with SHBG ≥ 76.653nmol/L. The stability of the association between SHBG and MetS was confirmed through subgroup analysis and sensitivity analysis. Conclusions Our results suggest that reduced SHBG levels are associated with an increased prevalence of MetS in adults, particularly when SHBG levels are below 76.653 nmol/L. More investigation is required to comprehend the mechanisms underlying these results and to delve into their clinical implications.

show abstract

Sex Hormone-Binding Globulin and Risk of Incident Dementia in Middle-Aged to Older Women: Results from the UK Biobank Cohort Study

Cited by 3 publications

References 31 publications

Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough

Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough

Association between sex hormone binding globulin and metabolic syndrome in US adults: insights from National Health and Nutrition Examination Survey (NHANES) 2013–2016

Correlation of Sex Hormone Binding Globulin with Metabolic Syndrome in US Adults: Insights from National Health and Nutrition Examination Survey (NHANES) 2013–2016

Contact Info

Product

Resources

About